Erratum for Wire et al., Lack of Clinically Significant Pharmacokinetic Interaction between the Thrombopoietin Receptor Agonist Eltrombopag and Hepatitis C Virus Protease Inhibitors Boceprevir and Telaprevir

Documenti analoghi

• Lack of Clinically Significant Pharmacokinetic Interaction between the Thrombopoietin Receptor Agonist Eltrombopag and Hepatitis C Virus Protease Inhibitors Boceprevir and Telaprevir
  di: Wire, Mary Beth, et al.
  Pubblicazione: (2014)
• Telaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity
  di: Carlson, Amanda, et al.
  Pubblicazione: (2013)
• Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
  di: Johnson, Mark, et al.
  Pubblicazione: (2014)
• Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
  di: Erickson-Miller, Connie L, et al.
  Pubblicazione: (2009)
• The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation
  di: Vogel, Jens-Uwe, et al.
  Pubblicazione: (2019)